BASAAspirin 81 mg vs 325 mg for Stroke Prevention in Head and Neck Vessels Injury

This clinical trial focuses on comparing the effectiveness of two different doses of Aspirin, 81 mg and 325 mg, in preventing strokes. The study involves patients who have experienced an injury to the blood vessels in their head and neck area. The main aim is to understand if the lower dose of Aspirin, 81 mg, is as effective as the higher dose, 325 mg, in stroke prevention. Additionally, the study also seeks to determine if the rate of bleeding complications is not higher in patients taking the lower dose. This research is important as it can help improve the care and treatment strategies for patients with such injuries. During the trial, participants are randomly assigned to take either Aspirin 81 mg or Aspirin 325 mg. The primary outcome being measured is the number of patients who experience a new stroke event, which could be either an ischemic stroke (caused by blood clots) or a hemorrhagic stroke (caused by bleeding in the brain). The study is designed to evaluate how well each dose of Aspirin prevents these events while also monitoring for any potential side effects or complications.